Mar 17, 2025 9:15am EDT TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
Mar 05, 2025 9:00am EST TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
Feb 25, 2025 9:20am EST TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
Jan 29, 2025 9:15am EST TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
Jan 15, 2025 9:15am EST TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
Dec 19, 2024 9:15am EST TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
Dec 09, 2024 9:00am EST TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
Oct 02, 2024 9:10am EDT TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
Aug 21, 2024 9:00am EDT TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
Jul 24, 2024 9:05am EDT TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
